Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670994 · ClinicalTrials.gov registry record · Phase 1
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Altor BioScience.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01670994: Clinical Trial Phase 1 study, sponsored by Altor BioScience.
NCT01670994 is a Phase 1 study that was terminated before completion, run by Altor BioScience. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01670994, a Phase 1 study, was terminated before completion, sponsored by Altor BioScience.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.
Primary Outcome
Number of treatment related AEs that occur or worsen after the first dose of study treatment
Interventions
- BIOLOGICAL ALT-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-08-14 |
| Est. Completion | 2015-09-09 |
| Phase | Phase 1 |
Why NCT01670994 stopped before completion
NCT01670994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which ALT-801 is the first listed.
NCT01670994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01670994 about?
NCT01670994 is a clinical study titled "QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma". This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.
What is the current status of trial NCT01670994?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-08-14. Estimated completion is 2015-09-09.
What interventions are being tested in trial NCT01670994?
The interventions under investigation include: ALT-801 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01670994?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01670994's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI